Arcus Biosciences (NYSE:RCUS) Reaches New 52-Week Low – Should You Sell?

Arcus Biosciences, Inc. (NYSE:RCUS) shares hit a new 52-week low on Tuesday . The stock traded as low as $10.12 and last traded at $10.16, with a volume of 1208651 shares. The stock had previously closed at $11.07.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on RCUS shares. Wedbush restated an “outperform” rating and set a $36.00 target price on shares of Arcus Biosciences in a research report on Thursday, November 7th. HC Wainwright upgraded shares of Arcus Biosciences from a “neutral” rating to a “buy” rating and increased their price target for the company from $18.00 to $24.00 in a research report on Wednesday. Morgan Stanley lowered their price target on shares of Arcus Biosciences from $36.00 to $25.00 and set an “overweight” rating on the stock in a research report on Tuesday, February 18th. Finally, Bank of America reduced their price objective on shares of Arcus Biosciences from $22.00 to $17.00 and set a “neutral” rating on the stock in a research note on Wednesday, February 19th. One investment analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $30.25.

Arcus Biosciences Price Performance

The company has a market cap of $1.04 billion, a PE ratio of -3.13 and a beta of 0.84. The business’s 50 day moving average price is $13.57 and its 200-day moving average price is $15.46. The company has a quick ratio of 5.24, a current ratio of 5.24 and a debt-to-equity ratio of 0.08.

Arcus Biosciences (NYSE:RCUS) last posted its quarterly earnings data on Tuesday, February 25th. The company reported ($1.03) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.17) by $0.14. The company had revenue of $36.00 million for the quarter, compared to analyst estimates of $29.38 million. Arcus Biosciences had a negative net margin of 102.66% and a negative return on equity of 45.59%. As a group, analysts forecast that Arcus Biosciences, Inc. will post -3.15 earnings per share for the current year.

Insider Activity

In other news, CFO Robert C. Goeltz II sold 3,594 shares of the firm’s stock in a transaction that occurred on Tuesday, December 31st. The shares were sold at an average price of $15.00, for a total transaction of $53,910.00. Following the completion of the sale, the chief financial officer now owns 60,138 shares of the company’s stock, valued at approximately $902,070. This trade represents a 5.64 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 12.30% of the company’s stock.

Hedge Funds Weigh In On Arcus Biosciences

A number of hedge funds have recently added to or reduced their stakes in RCUS. GSA Capital Partners LLP boosted its holdings in Arcus Biosciences by 17.8% in the third quarter. GSA Capital Partners LLP now owns 187,415 shares of the company’s stock worth $2,866,000 after purchasing an additional 28,307 shares during the period. Quest Partners LLC boosted its holdings in shares of Arcus Biosciences by 40,904.3% during the third quarter. Quest Partners LLC now owns 9,431 shares of the company’s stock valued at $144,000 after acquiring an additional 9,408 shares during the period. BNP PARIBAS ASSET MANAGEMENT Holding S.A. boosted its holdings in shares of Arcus Biosciences by 25.1% during the third quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 931,048 shares of the company’s stock valued at $14,236,000 after acquiring an additional 186,750 shares during the period. Intech Investment Management LLC acquired a new position in shares of Arcus Biosciences during the third quarter valued at $244,000. Finally, Massachusetts Financial Services Co. MA boosted its holdings in shares of Arcus Biosciences by 39.0% during the third quarter. Massachusetts Financial Services Co. MA now owns 80,889 shares of the company’s stock valued at $1,237,000 after acquiring an additional 22,716 shares during the period. Institutional investors and hedge funds own 92.89% of the company’s stock.

Arcus Biosciences Company Profile

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.